Kevin D. Foust

The Ohio State University — United States

Medicine · Health Sciences

34h-index10.8kcitations74works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Neurogenetic and Muscular Disorders Research(47), RNA modifications and cancer(22), Virus-based gene therapy research(20), CRISPR and Genetic Engineering(14), RNA Interference and Gene Delivery(11)

Publications74 total

Novel MECP2 gene therapy is effective in a multicenter study using two mouse models of Rett syndrome and is safe in non-human primates
Molecular Therapy·2023· 22 citedOpen Access
Retraction Note: Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN
Nature Biotechnology·2022· 12 citedOpen Access
Biodistribution of onasemnogene abeparvovec DNA, mRNA and SMN protein in human tissue
Nature Medicine·2021· 96 cited
O.24Biodistribution of onasemnogene abeparvovec (AVXS-101) DNA, mRNA, and SMN protein in human tissue
Neuromuscular Disorders·2019· 3 cited
Intrathecal AAV9-SOD1-shRNA Administration for Amyotrophic Lateral Sclerosis (S5.003)
Neurology·2019· 2 cited
Rett syndrome gene therapy improves survival and ameliorates behavioral phenotypes in MeCP2 null (S51.002)
Neurology·2019· 6 cited
IP 853. AVXS-101 Phase-1-Gene Therapy Clinical Trial in SMA Type 1: Event-Free Survival and Achievement of Developmental Milestones
Neuropediatrics·2018
SMA THERAPIES I
Neuromuscular Disorders·2018
AVXS-101 Phase 1 Gene Replacement Therapy Clinical Trial in SMA Type 1: Patients Treated Early with the Proposed Therapeutic Dose Were Able to Sit Unassisted at a Younger Age (S29.002)
Neurology·2018· 1 cited
AVXS-101 Phase 1 Gene Replacement Therapy Clinical Trial in SMA Type 1: Continued Event Free Survival and Achievement of Developmental Milestones (S29.001)
Neurology·2018· 7 cited
AVXS-101 Phase 1 Gene Replacement Therapy Clinical Trial in SMA Type 1: Continued Independence from Nutritional and Ventilatory Support in Patients Dosed Early in Disease Progression (S29.003)
Neurology·2018· 1 cited
Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care
Neuromuscular Disorders·2017· 992 citedOpen Access
Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy
New England Journal of Medicine·2017· 2.2k citedOpen Access
AVXS-101 phase 1 gene therapy clinical trial in SMA Type 1: patients treated early with the proposed therapeutic dose were able to sit unassisted at a younger age
Neuromuscular Disorders·2017· 7 cited
Systemic gene delivery transduces the enteric nervous system of guinea pigs and cynomolgus macaques
Gene Therapy·2017· 21 citedOpen Access
AVXS-101 Phase 1 gene therapy clinical trial in SMA Type 1: Interim data demonstrates improvements in supportive care use
European Journal of Paediatric Neurology·2017· 2 cited
AVXS-101 Phase 1 gene therapy clinical trial in SMA Type 1: Event free survival and achievement of developmental milestones
European Journal of Paediatric Neurology·2017· 3 cited
CSF delivery of AAV9-mediated gene therapy for SMA, a lethal neuromuscular disease in children: a dose-response study in mice and nonhuman primates (P3.133)
Neurology·2017
AVXS-101 Phase 1 Gene Therapy Clinical Trial in SMA Type 1: Experience with pre-existing anti-AAV9 antibody in the SMA1 population (S13.001)
Neurology·2017· 4 cited
AVXS-101 Phase 1 Gene Therapy Clinical Trial in SMA Type 1: Correlation between CHOP-INTEND and Motor Milestone achievements (S13.002)
Neurology·2017· 3 cited
page 1 of 4Next →

Frequent Co-authors

Brian K. Kaspar(33), Arthur H.M. Burghes(21), Kathrin Meyer(14), Jerry R. Mendell(13), Shibi Likhite(13), Lyndsey Braun(12), Vicki L. McGovern(11), W. David Arnold(9), Thomas W. Prior(9), Richard Shell(8), Louise R. Rodino‐Klapac(8), Linda Lowes(8), Lindsay N. Alfano(8), Katherine Berry(8), James L’Italien(8), Douglas M. Sproule(8), Samiah Al-Zaidy(7), Kathleen Church(7), John T. Kissel(7), Carlos J. Miranda(7)